Clinical Trials Browser

Completed × Neoplasms × Immune Checkpoint Inhibitors × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT04417465 2025-09-25

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Phase 1 Completed

101 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04681131 2025-09-25

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Phase 2 Completed

85 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Phase 1/2 Completed

245 enrolled

Sarcoma

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT03868046 2025-04-01

AUTENTIC

Completed

242 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05934214 2024-03-05

EXIT

Completed

141,630 enrolled

Tumor-Agnostic

Neoplasms

NCT03790488 2023-07-03

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Phase 1 Completed

18 enrolled

Tumor-Agnostic

Neoplasms

NCT03492242 2019-09-26

CHIMeRA

Completed

1,000 enrolled

Arthritis, Autoimmune Diseases, Endocrine System Diseases, Eye Diseases, Heart Diseases, Myositis, Neoplasms

Clinical Trials

SARCO-CTI

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

AUTENTIC

EXIT

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

CHIMeRA